

# **Real-time forecasting the trajectory of monkeypox outbreaks at the national and global levels, July – October 2022.**

Amanda Bleichrodt<sup>1</sup>, Sushma Dahal<sup>1</sup>, Kevin Maloney<sup>1</sup>, Lisa Casanova<sup>1</sup>, Ruiyan Luo<sup>1</sup>, Gerardo Chowell\*<sup>1</sup>

A.B. and S.D. contributed equally to this work

<sup>1</sup> Department of Population Health Sciences, School of Public Health, Georgia State University, Atlanta, GA, USA.

\*Corresponding author: Dr. Gerardo Chowell ([gchowell@gsu.edu](mailto:gchowell@gsu.edu))

## Abstract

### *Background*

Beginning May 7, 2022, multiple nations reported an unprecedented surge in monkeypox cases. Unlike past outbreaks, differences in affected populations, transmission mode, and clinical characteristics have been noted. With the existing uncertainties of the outbreak, short-term forecasting can guide and evaluate the effectiveness of public health measures.

### *Methods*

We obtained publicly available data on confirmed weekly cases of monkeypox at the global level and for seven countries (with the highest burden of disease at the time this study was initiated) from the Our World in Data (OWID) GitHub repository and CDC website. We generated short-term forecasts of new cases of monkeypox across the study areas using an ensemble n-sub-epidemic modeling framework based on weekly cases using 10-week calibration periods. We report and assess the weekly forecasts with quantified uncertainty from the top-ranked, second-ranked, and ensemble sub-epidemic models. Overall, we conducted 324 weekly sequential 4-week ahead forecasts across the models from the week of July 28th, 2022, to the week of October 13th, 2022.

### *Results*

The last 10 of 12 forecasting periods (starting the week of August 11<sup>th</sup>, 2022), show either a plateauing or declining trend of monkeypox cases for all models and areas of study. According to our latest 4-week ahead forecast from the top-ranked model, a total of 6232 (95% PI: 487.8,

12468.0) cases could be added globally from the week of 10/20/2022 to the week of 11/10/2022. At the country level, the top-ranked model predicts that the United States will report the highest cumulative number of new cases for the 4-week forecasts (median based on OWID data: 1806 (95% PI: 0.0, 5544.5)). The top-ranked and weighted ensemble models outperformed all other models in short-term forecasts.

## ***Conclusions***

Our top-ranked model consistently predicted a decreasing trend in monkeypox cases on the global and country-specific scale during the last ten sequential forecasting periods. Our findings reflect the potential impact of increased immunity, and behavioral modification among high-risk populations.

## ***Keywords***

Monkeypox, Real-time forecasts, Mathematical model, Sub-epidemic, Ensemble model, Global, Country-level

## Background

On May 7th, 2022, a case of monkeypox with recent travel to Nigeria was reported in England [1, 2]. Shortly after, the Centers for Disease Control and Prevention (CDC) identified a case of monkeypox in Massachusetts on May 15th, 2022 [3]. Since then, multiple nations, including the U.S., have reported a surge in monkeypox cases, mostly among males within the communities of gay, bisexual, and other men who have sex with men (MSM) [4-6]. The World Health Organization (WHO) declared monkeypox a global health emergency on July 23rd, 2022 [7]. As of October 31th, 2022, over 76,000 monkeypox cases have been reported in non-endemic countries, especially in the US, Spain, and Brazil, during the ongoing outbreak [8]. Given that this is an emerging infection in non-endemic countries, with little historical information about how outbreaks might unfold, mathematical models can help generate real-time forecasts of the trajectory of the epidemics and guide public health measures appropriate for a given geographic setting.

Monkeypox is an endemic zoonotic virus in Africa, most similar in clinical presentation to the Variola (Smallpox) virus [9]. Both are part of the *Orthopoxvirus* genus, which includes other viruses such as cowpox and Vaccinia virus - used in smallpox vaccines [9, 10]. Monkeypox symptoms include, but are not limited to, flu-like symptoms followed by a raised rash on the face and extremities. The incubation period is usually 6-13 days, with a symptomatic period ranging from 2 to 4 weeks [9]. Fortunately, monkeypox is not an airborne pathogen. Instead, transmission is mainly driven by prolonged close contact with infected individuals or direct contact with skin lesions, respiratory secretions, or recently contaminated objects - a feature that may facilitate control through basic public health measures [9].

The ability to forecast country-specific epidemic trajectories is particularly useful in an outbreak like this, which paints a unique epidemiological picture compared to past outbreaks within both endemic and non-endemic countries [4, 6, 11, 12]. For instance, sexual and intimate contact, specifically between men, has driven the great majority of infections [5, 13, 14]. Likewise, over 98% of cases in the United States and Spain are male, and most have identified as MSM [13, 15]. Cases of the ongoing outbreak are less likely to report prodromal symptoms, and rash occurs most frequently in the genital region [4, 13]. The scale of community spread is unprecedented [16].

While much has been learned about the epidemiology of this emerging outbreak during the last few months, substantial uncertainties remain about the effect of several variables on the epidemic trajectory, including the frequency and role of asymptomatic individuals, the role of pre-existing immunity from previous smallpox immunization campaigns, and the efficacy of available vaccines [17]. In this context, semi-mechanistic growth models are especially suitable for conducting short-term forecasts to guide response efforts and evaluate the impact of control measures, including behavior changes that mitigate transmission rates, contact tracing, and vaccination, on growth trends [18]. Here, we employ an ensemble sub-epidemic modeling framework to characterize epidemic trajectories that result from sub-epidemics aggregation through an optimization process [19]. This framework has yielded competitive performance in short-term forecasts of various infectious disease outbreaks [19, 20]. In this study, we generate 4-week ahead forecasts of laboratory-confirmed cases of monkeypox in near real-time at the global level and for nations that have reported the great majority of the cases: Brazil, Canada, England, France, Germany, Spain, and the United States. We also evaluate the model fit and performance

of the forecasts based on the mean absolute error (MAE), mean square error (MSE), 95% prediction interval coverage (PI), and weighted interval score (WIS).

## Methods

### *Data*

We obtained weekly updates of the daily confirmed monkeypox cases by reporting date from publicly available sources by the CDC and the Our World in Data (OWID) GitHub repository [21, 22]. At the global level and for countries that have reported the great majority of the cases, including Brazil, Canada, England, France, Germany, Spain, and the United States, we retrieved daily case series from the GitHub Our World in Data (OWID) repository [8, 22]. We reported forecasts based on CDC and OWID team data for the United States. The CDC and OWID data sources define a confirmed case as a person with a laboratory-confirmed case of monkeypox [23, 24]. Data were downloaded every Wednesday evening from the CDC and every Friday afternoon from the GitHub Our World in Data (OWID) repository from the week of July 28th, 2022, through the week of October 13th, 2022. For the week of July 28th, 2022, data posted by the OWID team on August 9th, 2022, was used to produce the forecast as it was the earliest data available.

### *The n-sub-epidemic modeling framework*

A detailed description of our modeling framework is given in ref. [19]. In this n-sub-epidemic modeling framework, epidemic trajectories are modeled as the aggregation of

overlapping and asynchronous sub-epidemics. A sub-epidemic follows the 3-parameter generalized-logistic growth model (GLM), which has displayed competitive performance [25-27]. This model is given by the following differential equation:

$$\frac{dC(t)}{dt} = C'(t) = rC^p(t) \left(1 - \frac{C(t)}{K_0}\right),$$

where  $C(t)$  denotes the cumulative number of cases at time  $t$  and  $\frac{dC(t)}{dt}$  describes the curve of daily cases over time  $t$ . The parameter  $r$  is positive, denoting the growth rate per unit of time,  $K_0$  is the final outbreak size, and  $p \in [0,1]$  is the "scaling of growth" parameter which allows the model to capture early sub-exponential and exponential growth patterns. If  $p = 0$ , this equation describes a constant number of new cases over time, while  $p = 1$  indicates that the early growth phase is exponential. Intermediate values of  $p$  ( $0 < p < 1$ ) describe early sub-exponential (e.g., polynomial) growth dynamics.

An  $n$ -sub-epidemic trajectory comprises  $n$  overlapping sub-epidemics and is given by the following system of coupled differential equations:

$$\frac{dC_i(t)}{dt} = C'_i(t) = A_i(t)r_iC_i^{p_i}(t) \left(1 - \frac{C_i(t)}{K_{0i}}\right),$$

Where  $C_i(t)$  tracks the cumulative number of cases for sub-epidemic  $i$ , and the parameters that characterize the shape of the  $i_{th}$  sub-epidemic are given by  $(r_i, p_i, K_{0i})$ , for  $i = 1, \dots, n$ . Thus, the 1-sub-epidemic model is equivalent to the generalized growth model described above. When  $n > 1$ , we model the onset timing of the  $(i + 1)_{th}$  sub-epidemic, where  $(i + 1) \leq n$ , by

employing an indicator variable given by  $A_i(t)$  so that the  $(i + 1)_{th}$  sub-epidemic is triggered when the cumulative curve of the  $i_{th}$  sub-epidemic exceeds  $C_{thr}$ .

The  $(i + 1)_{th}$  sub-epidemic is only triggered when  $C_{thr} \leq K_{0i}$ . Then, we have:

$$A_i(t) = \begin{cases} 1, C_{i-1}(t) > C_{thr} \\ 0, Otherwise \end{cases} \quad i=2, \dots, n,$$

where  $A_1(t) = 1$  for the first sub-epidemic. Hence, the total number of parameters that are needed to model an  $n$ -sub-epidemic trajectory is given by  $3n + 1$ . The initial number of cases is given by  $C_1(0) = I_0$ , where  $I_0$  is the initial number of cases in the observed data. The cumulative curve of the  $n$ -sub-epidemic trajectory is given by:

$$C_{tot}(t) = \sum_{i=1}^n C_i(t).$$

Hence, this modeling framework is suitable for diverse epidemic patterns including those characterized by multiple peaks.

### ***Parameter estimation for the $n$ -sub-epidemic model***

The time series of new weekly monkeypox cases are denoted by:

$$y_{t_j} = y_{t_1}, y_{t_2}, \dots, y_{t_{n_d}} \text{ where } j = 1, 2, \dots, n_d$$



Here,  $t_j$  are the time points for the time series data,  $n_d$  is the number of observations. Using these case series, we estimate a total of  $3n + 1$  model parameters, namely  $\theta = (C_{thr}, r_1, p_1, K_{0_1}, \dots, r_n, p_n, K_{0_n})$ . Let  $f(t, \theta)$  denote the expected curve of new monkeypox cases of the epidemic's trajectory. We can estimate model parameters by fitting the model solution to the observed data via nonlinear least squares [28] or via maximum likelihood estimation assuming a specific error structure [29]. For nonlinear least squares, this is achieved by searching for the set of parameters  $\hat{\theta}$  that minimizes the sum of squared differences between the observed data  $y_{t_j} = y_{t_1}, y_{t_2}, \dots, y_{t_{n_d}}$  and the model mean  $f(t, \theta)$ . That is,  $\theta = (C_{thr}, r_1, p_1, K_{0_1}, \dots, r_n, p_n, K_{0_n})$  is estimated by  $\hat{\theta} = \arg \min \sum_{j=1}^{n_d} (f(t_j, \theta) - y_{t_j})^2$ .

We quantify parameter uncertainty using a bootstrapping approach described in [30], which allows the computation of standard errors and related statistics in the absence of closed-form solutions. To that end, we use the best-fit model  $f(t, \hat{\theta})$  to generate  $B$ -times replicated simulated datasets of size  $n_d$ , where the observation at time  $t_j$  is sampled from a normal distribution with mean  $f(t_j, \hat{\theta})$  and variance  $\frac{\sum_{j=1}^{n_d} (f(t_j, \hat{\theta}) - y_{t_j})^2}{n_d - (3n + 1)}$ . Then, we refit the model to each  $B$  simulated dataset to re-estimate each parameter. The new parameter estimates for each realization are denoted by  $\hat{\theta}_b$  where  $b = 1, 2, \dots, B$ . Using the sets of re-estimated parameters  $(\hat{\theta}_b)$ , the empirical distribution of each estimate can be characterized, and the resulting uncertainty around the model fit can similarly be obtained from  $f(t, \hat{\theta}_1), f(t, \hat{\theta}_2), \dots, f(t, \hat{\theta}_B)$ . We run the calibrated model forward in time to generate short-term forecasts with quantified uncertainty.

188

189 *Selecting the top-ranked sub-epidemic models*

We used the  $AIC_c$  values of the set of best fit models based on one and two subepidemics to select the top-ranked sub-epidemic models. We ranked the models from best to worst according to their  $AIC_c$  values, which is given by [31, 32]:

$$AIC_c = n_d \log(SSE) + 2m + \frac{2m(m+1)}{n_d - m - 1}$$

where  $SSE = \sum_{j=1}^{n_d} (f(t_j, \hat{\theta}) - y_{t_j})^2$ ,  $m = 3n + 1$  is the number of model parameters, and  $n_d$  is the number of data points. Parameters from the above formula for  $AIC_c$  are estimated from the nonlinear least-squares fit, which implicitly assumes normal distribution for error.

### ***Constructing ensemble n-sub-epidemic models***

We generate ensemble models from the weighted combination of the highest-ranking sub-epidemic models as deemed by the  $AIC_{c_i}$  for the  $i$ -th ranked model where  $AIC_{c_1} \leq \dots \leq AIC_{c_I}$  and  $i = 1, \dots, I$ . An ensemble derived from the top-ranking  $I$  models is denoted by Ensemble( $I$ ). Thus, Ensemble(2) refers to the ensemble model generated from the weighted combination of the top-ranking 2 sub-epidemic models. We compute the weight  $w_i$  for the  $i$ -th model,  $i = 1, \dots, I$ , where  $\sum w_i = 1$  as follows:

$$w_i = \frac{l_i}{l_1 + l_2 + \dots + l_I} \quad \text{for all } i = 1, 2, \dots, I,$$

where  $l_i$  is the relative likelihood of model  $i$ , which is given by  $l_i = e^{((AIC_{min} - AIC_i)/2)}$  [33], and hence  $w_l \leq \dots \leq w_1$ . The prediction intervals based on the ensemble model can be obtained using a bootstrap approach similar as before. We employed the first-ranked and the second-ranked models to derive the ensemble forecasts.  $AIC_c$  values of the top models for the most recent forecast can be found in supplementary figure 1s (Additional file 1).

### ***Forecasting strategy***

Using a 10-week calibration period for each model, we have conducted 324 real-time weekly sequential 4-week ahead forecasts across studied areas and models (week of July 28<sup>th</sup> – week of October 13<sup>th</sup>, 2022) thus far. At the national and global levels, we also report forecasting performance metrics for 8 sequential forecasting periods covering the weeks of July 28<sup>th</sup>, 2022, through September 15, 2022, for which data was available to assess the 4-weeks ahead forecasts. We also compare the predicted cumulative cases for the 4-week forecasts across models for a given setting. Cumulative cases for a given model were calculated as the sum of median number of new cases predicted during the 4-week forecast.

### ***Performance metrics***

Across geographic areas, we assessed the quality of our model fit and performance of the short-term forecasts for each model by using four standard performance metrics: the mean squared error (MSE) [34], the mean absolute error (MAE) [35], the coverage of the 95% prediction interval (PI) [34], and the weighted interval score (WIS) [36, 37]. While MSE and MAE assess the average deviations of the mean model fit to the observed data, the coverage of the 95% PI and the weighted interval score consider the uncertainty of the forecasts.

## Results

### *Performance of forecasts*

Table 1 summarizes the mean forecasting performance metrics of the models by geographic area. Supplementary figures 2s-10s, and supplementary tables 1s-4s show the forecasting performance metrics for each of the 8 sequential forecasts. Regarding the average MAE, MSE, and WIS across forecasting periods, the first-ranked and weighted ensemble models outperformed the other models for most studied areas except for France, the US (OWID), and the global level (Table 1, Supplementary table 5s). The individual MAE, MSE, and WIS values for each of the eight sequential forecasts evaluated are shown in supplementary tables 1s, 2s, and 4s, respectively (Additional file 2).

Regarding the 95% PI coverage, most models had similar coverage value across the 8 sequential forecasts. For example, in Canada, France, England, and Germany, all four models had the same 95% PI coverage in 7 of 8 forecasts, with lower coverage value during early forecasting periods (25% to 75%) and higher coverage value during later forecasting periods (100%) (Supplementary table 3s). Across 72 forecasts involving all study areas (2 datasets for the U.S.), 54.17% (39/72) of the 95% PI coverage was 100% for all four models. In general, the 95% PI coverage improved during the declining phase compared to the earlier periods (Supplementary figures 2s-10s). Figures 1-9 show the forecasts for the weighted ensemble model for each study area while the forecasts from the top-ranked and second-ranked models are given in supplementary figures (Additional file 1).

## *Performance of the model fit*

The mean calibration performance metrics are shown in supplementary table 6s. Overall, the sub-epidemic models yielded good fits for the 10-week calibration periods. In terms of the mean MAE, the second-ranked model performed better than the other models in all the study areas. Likewise, the second-ranked model outperformed other models in terms of mean MSE in all the study areas except Canada. In terms of mean WIS, the unweighted ensemble model performed better than the other 55.5% of the time. The coverage of the 95% PI coverage was consistently 100% across models and study areas except for France, where for the recent two forecast periods, the top-ranked and the weighted ensemble models reached 90% coverage. The performance metrics for each sequential calibration period are shown in supplementary tables 7s-10s (Additional file 2) and supplementary figures 29s-37s (Additional file 1).

## *Global forecasts*

Based on the global trend, our latest 4-week ahead forecasts from the three models continue to support a significant slowdown in the growth rate of monkeypox (Figures 10, 11, 12). Our most recent forecasts for the week of October 13th, 2022, predict a short-term decline in the number of new cases reported worldwide. According to our latest forecasts from the top-ranked model and weighted ensemble model, a total of 6232 (95% PI: 487.8, 12468.0 and 95% PI: 492.8, 12463.1) cases could be added globally during the 4 weeks from October 20th to the week of November 10, 2022 (Table 2, Supplementary table 12s).

The uncertainty of the cumulative predicted median cases was higher for the second-ranked model compared to the top-ranked and ensemble models for most forecasts. For example, for Brazil, the 95% prediction interval for the cumulative median forecasts generated during the week of August 25, 2022, was 1288 to 3903 for the top-ranked model and ensemble model compared to 1038 to 27926 for the second-ranked model (Supplementary figure 41s, Table 2, Supplementary table 11s). The cumulative predicted median number of cases for each of the models across 12 sequential forecasting weeks for all study areas are shown in table 2 (top-ranked model), supplementary table 11s (second-ranked model), supplementary table 12s (weighted ensemble model), supplementary table 13s (unweighted ensemble model) and supplementary figures 38s-46s.

### *Country-level forecasts*

Our most recent forecasts from the top-ranked, second-ranked, and the corresponding ensemble sub-epidemic model support a continued declining trend for each of the seven countries (Figures 10, 12). However, the upper 95% PI of the forecast for Brazil derived from the second-ranked sub-epidemic model, albeit with substantially reduced statistical support, indicates the possibility of a further increasing trend in the number of new cases starting late October 2022 (Figure 11). Out of a total of 324 forecasts generated from the week of July 28<sup>th</sup> through the week of October 13<sup>th</sup> 2022, for all study areas across the three models, 306 (94.4%) forecasts showed a declining trend of monkeypox cases (Figures 1-9, Supplementary figures 11s-28s).

The United States exhibited a slow increase in cases from late May 2022 until late June 2022, followed by a rapid increase, peaking during early to mid-August 2022. According to our latest forecasts from the weighted ensemble model, a maximum of 1604 and 554 cases could be added from the week of October 20th to the week of November 10, 2022, in the U.S. based on the CDC data and the OWID data, respectively (Supplementary table 12s, Supplementary figures 39s, 40s). The uncertainty of the predictions based on OWID data is higher than those based on the CDC data (Figures 10, 11, 12; Supplementary figures 30s, 40s).

The epidemic curve peaked earliest in Germany in late June 2022. Two weeks later, in mid-July, the epidemic peaked in England. However, the epidemics in the U.S. and Brazil seem to have peaked later, during early August and mid-August, respectively. For Brazil, the top-ranked model predicted the possibility of adding a median of 879 cases (95% PI: 25, 1952) during the 4 weeks until November 10, 2022 (Table 2; Supplementary figure 41s). Similarly, based on the top-ranked model, Germany and England could each add a median 1.5 (95% PI: 0, 126) and 2.7 (95% PI: 0, 343) cases, respectively, between the week of October 20 to November 10, 2022 (Table 2; Supplementary figures 42s, 43s). Likewise, for France, Spain, and Canada, the number of cases peaked during the week of July 14-July 21, 2022, followed by a decline in the number of reported new cases. During the most recent 4-week ahead forecast, the top-ranked model predicted very few cases (in terms of median value) of monkeypox in France (median:10, 95% PI: 0, 1088), Spain (median: 43, 95% PI:0, 316), and Canada (median:14, 95% PI: 0, 90) (Table 2, Supplementary figure 44s, 45s, 46s).

It is reassuring that the cumulative number of new cases predicted for the weeks of September 29th, October 6th, and October 13th, 2022, show a declining pattern for Germany, France, and England, indicating a significant reduction in the growth rate (Table 2,

Supplementary figures 42s- 44s). For Brazil, the pattern in the number of cumulative cases in 4-week ahead predictions has consistently declined from the week of September 15 to the week of October 13 (from 2402 to 879, 63.4% decline) (Table 2, Supplementary figure 41s). For the forecasts generated during the last three weeks (September 29th, October 6th, and October 13th), the predicted median cumulative cases remain below 50 for Canada and England, below 10 for Germany, and below 70 for Spain, suggesting that the trend is stabilizing at low case numbers (Table 2, Supplementary figure 42s, 43s, 45s, 46s). Table 2, supplementary tables 11s-13s (Additional file 2), and supplementary figures 38s-46s (Additional file 1) summarize the forecasting results for each model. Our forecast for the United States can be found in our GitHub repository [38] and on our webpage [39].

## Discussion

We report results from short-term (4 weeks ahead) forecasts of monkeypox cases using a sub-epidemic modeling framework for the world and seven countries that, at the time this study began, had reported the great majority of cases. To our knowledge, this is the first study to report real-time sequential short-term forecasts of new monkeypox cases at the global and country level and to evaluate the performance of the models used to produce the forecasts. Our forecasts continue to support an overall declining trend in the number of new cases of monkeypox at the global and country-specific levels. Based on the top-ranked model and weighted ensemble model, we predict that during the next four weeks (the week of October 20th, 2022, through the week of November 10, 2022), a total 6232 (95% PI: 487.8, 12468.0, and 95% PI: 492.8, 12463.1) cases of monkeypox could be added globally. At the country level, our top-ranked



model indicates that the highest number of new cases will be reported in the United States (OWID data) (median: 1806, 95% PI: 0, 5545) followed by Brazil (median: 879, 95% PI: 25, 1952) and Spain (median: 43, 95% PI: 0, 316). Overall, our models have performed reasonably well across study areas. The top-ranked and weighted ensemble model outperformed other models on average in forecasting performance.

Our results offer valuable information to policymakers to guide the continued allocation of resources and inform mitigation efforts. More broadly, findings suggest that the epidemic could be brought under near-complete control in some regions should public health measures continue to be sustained, especially among the high-risk groups [40-42]. Indeed, a core group of higher-risk people is thought to disproportionately contribute to transmission and thereby sustain sexually transmitted infection (STI) epidemics. Monkeypox is inherently different from other STIs like HIV, which has a lifelong duration, or bacterial STIs, which can be acquired repeatedly. Cases may decline rapidly as immunity increases among core group members, either due to infection or vaccination. Without a core group driving the epidemic, monkeypox may become endemic with low transmission levels [43-45]. The current monkeypox outbreak is unprecedented in size and geographic scope. As of October 31th, 2022, a total of 109 countries globally have reported monkeypox cases at 77,092 [8]. Only seven countries have historically reported monkeypox cases indicating that more than 93% of the countries reporting cases are non-endemic to monkeypox [8]. Our latest short-term forecasts from top-ranked models and weighted ensemble models conducted in near real-time indicate a clear, continued slow-down in the number of new cases globally and in each country included in the study. This mirrors the recent continental declines in cases reported for Europe and the Americas [41, 46, 47].

Findings support the significant impact of current measures to contain the outbreak in

different areas. For example, in the United States, the primary strategy has been a combination of increasing education around monkeypox (e.g., symptoms, transmission), encouraging practices that reduce potential close contacts and increasing access to vaccination and testing for high-risk groups [48-50]. Although supply-chain shortages impacted early vaccine access, as of August 26th, 2022, the availability of monkeypox vaccines had increased to sufficient levels to combat the outbreak. The racial disparities in access to vaccines that arose in late August are continuing to persist [51-53] though some progress has been made in improving the monkeypox vaccination among racial and ethnic minority groups in the US. For example, according to a recent morbidity and mortality weekly report (MMWR), between May 22–June 25 and July 31–October 10, 2022, the proportion of monkeypox vaccine recipients increased from 15% to 23% among Hispanic and from 6% to 13% among Black population [54]. In addition, although vaccines are more recently available, behavioral modification within high-risk groups appears to be driving declines in cases. Continuing these behaviors (e.g., limiting one-time sexual encounters) is crucial in slowing the transmission of monkeypox [5, 40, 55]. Based on the early evidence from Europe, the World Health Organization (WHO) is quite optimistic that the current outbreak of monkeypox can be contained with the improvement in vaccine supply chains in addition to early detection of the cases and educational interventions which lead to behavioral modifications in the high-risk groups [56]. Moreover, recent research indicates that the majority of monkeypox cases resulting in severe disease or death have been among MSM with compromised immune systems (e.g., due to untreated HIV infection). Specifically, increased burden has been noted among Black populations, and those experiencing mental health challenges or housing insecurities, reflecting the existing inequities in access to resources diagnosis, treatment, and prevention of monkeypox [57].

Our study is not exempt from limitations. First, our analysis relied on weekly time series data of lab-confirmed monkeypox cases from two sources, which display irregular daily reporting patterns [21, 22]. These sources use different approaches in compiling data and addressing data issues, which affect the characterization of the epidemic curve. For example, the CDC data uses cases with reporting data that includes either the positive laboratory test report date, CDC call center reporting date, or case data entry date into CDC's emergency response common operating platform [21]. The OWID team uses laboratory-confirmed case data reported to the World Health Organization via WHO Member States [22, 58]. In addition, the data used for forecasting could also be underestimated due to delays between the date of testing and the date of reporting. Because we are dealing with limited epidemic data in this study, we often examined forecasts derived from the second-ranked sub-epidemic model even when it yielded substantially diminished statistical support relative to the top-ranked model. The models employed in this study are semi-mechanistic in that they give insight into the nature of the process that generated the epidemic trends in terms of the aggregation of sub-epidemic trajectories. However, the models are not intended to quantify the effects of different factors, such as behavior change and vaccination, on the declining trend. Finally, it should be noted that our short-term forecasts are based on the inherent assumption that current behavior practices will not change substantially, at least over short time horizons. Further, our models are not sensitive to long-term forecasting episodic risk behaviors that are seasonal or event specific (e.g., LGBTQ Pride festivals). For example, a previous study has reported episodic risk behaviors among MSM, such as condomless anal sex with new male sex partners while vacationing [59].

In future work, we plan to systematically assess the forecasting performance of the models against other competing models, such as the Autoregressive Integrated Moving Average

(ARIMA), which has been broadly applied to forecast time series of epidemics and various other phenomena such as the weather and the stock market [19, 60, 61]. During the COVID-19, this sub-epidemic modeling framework demonstrated reliable forecasting performance in 10 to 30-day ahead forecasts of daily deaths, outperforming ARIMA models in weekly short-term forecasts covering the U.S. trajectory of the COVID-19 pandemic from the early phase of spring 2020 to the Omicron-dominated wave [19].

## Conclusions

In summary, real-time forecasting during epidemic emergencies offers actionable information that governments can use to anticipate healthcare needs and strategize the intensity and configuration of public health interventions. Our study provides and assesses near-real time short-term forecasts of monkeypox cases globally and for seven countries that have reported a higher number of cases for a large part of the epidemic. Our models continue to predict a slowdown in the incidence of monkeypox both at the global and country levels. Overall, our models have demonstrated utility in providing short-term forecasts, capturing the growth rate slowdown and peak timing with reasonable accuracy. Our findings likely reflect the impact of increased immunity and behavioral modification among high-risk populations.

430

431

## 432 **List of Abbreviations**

433 *ARIMA*: Autoregressive Integrated Moving Average model

434 *CDC*: The Centers for Disease Control and Prevention

435 *OWID*: Our World in Data

436 *LGBTQ*: Lesbian, Gay, Bisexual, Transgender, and Queer/Questioning

437 *MAE*: Mean Absolute Error

438 *MSE*: Mean Square Error

439 *MSM*: Men who have sex with men

440 *PI*: Prediction interval

441 *STI*: Sexual transmitted illness

442 *WHO*: World Health Organization

443 *WIS*: Weighted Interval Score

444

445

446

447

448

449

## 450 **Declarations**

451 *Ethics approval and consent to participate*

452 Not applicable.

453

454 *Consent for publication*

455 Not applicable.

456

457 *Availability of data and materials*

458 The datasets analyzed during the current study include the U.S. Monkeypox Case Trends  
 459 Reported to CDC data [[https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-](https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html)  
 460 [trends.html](https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html)] and data available from the Our World in Health Monkeypox GitHub repository  
 461 [<https://github.com/owid/monkeypox>]. The forecast generated during the current study are  
 462 available in the Monkeypox short term Forecasts, USA GitHub repository  
 463 [<https://github.com/gchowell/monkeypox-usa>] and the Monkeypox Forecasting Center website  
 464 [<https://publichealth.gsu.edu/research/monkeypox-forecasting-center/>].

465 *Competing interest*

466 The authors declare that they have no competing interests.

467 *Funding*

468 A.B. and S.D. are supported by a 2CI fellowship from Georgia State University. G.C. is  
469 partially supported from NSF grants 1610429 and 1633381 and R01 GM 130900.

470

471 *Authors' contributions*

472 A.B., S.D. and G.C. analyzed the data. A.B. and G.C. retrieved and managed data; A.B., S.D.  
473 R.L., and G.C. wrote the first draft of the manuscript. All authors contributed to writing and  
474 revising subsequent versions of the manuscript. All authors read and approved the final  
475 manuscript.

476

477 *Acknowledgements*

478 We would like to acknowledge the GSU Advanced Research Computing Technology &  
479 Innovation Core (ARCTIC) team for their help with the development of the monkeypox forecast  
480 website.

481

482

483

484

485

486

## References

1. Monkeypox cases confirmed in England – latest updates. In: Infectious diseases GOV.UK. . 2022. <https://www.gov.uk/government/news/monkeypox-cases-confirmed-in-england-latest-updates>. Accessed 2 Sep 2022.
2. WHO. Monkeypox - United Kingdom of Great Britain and Northern Ireland. In: Disease Outbreak News. World Health Organization 2022. <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON383>. Accessed 2 Sep 2022.
3. Scales A. Massachusetts public health officials confirm case of monkeypox. In: News. Massachusetts Department of Public Health. 2022. <https://www.mass.gov/news/massachusetts-public-health-officials-confirm-case-of-monkeypox>. Accessed 2 Sep 2022.
4. Philpott D. Epidemiologic and clinical characteristics of monkeypox cases—United States, May 17–July 22, 2022. MMWR Morbidity and Mortality Weekly Report. 2022; 71.
5. Spicknall IH, Pollock ED, Clay PA, Oster AM, Charniga K et al. Modeling the impact of sexual networks in the transmission of Monkeypox virus among gay, bisexual, and other men who have sex with men—United States, 2022. MMWR Morbidity and Mortality Weekly Report. 2022; 71(35):1131-1135.
6. Monkeypox outbreak 2022 – Global. <https://www.who.int/emergencies/situations/monkeypox-oubreak-2022>. Accessed 29 Oct 2022.



- 510 7. Monkeypox declared a global health emergency by the World Health Organization. In:  
511 Health U.N. News 2022. <https://news.un.org/en/story/2022/07/1123152>. Accessed 3 Sep  
512 2022.
- 513 8. Global Map & Case Count.  
514 <https://www.cdc.gov/poxvirus/monkeypox/response/2022/world-map.html>. Accessed 1  
515 Nov 2022.
- 516 9. WHO. Key facts. In: Monkeypox. World Health Organization. 2022.  
517 <https://www.who.int/news-room/fact-sheets/detail/monkeypox>. Accessed 2 Sep 2022.
- 518 10. Poxvirus Diseases. <https://www.cdc.gov/poxvirus/diseases.html>. Accessed 2 Sep 2022.
- 519 11. Past U.S. Cases & Outbreaks. [https://www.cdc.gov/poxvirus/monkeypox/outbreak/us-](https://www.cdc.gov/poxvirus/monkeypox/outbreak/us-outbreaks.html)  
520 [outbreaks.html](https://www.cdc.gov/poxvirus/monkeypox/outbreak/us-outbreaks.html). Accessed 2 Sep 2022.
- 521 12. Mandavilli A. Three Pressing Questions About Monkeypox: Spread, Vaccination,  
522 Treatment. In: Monkeypox. The New York Times. 2022.  
523 <https://www.nytimes.com/2022/07/29/health/monkeypox-spread-vaccine-treatment.html>.  
524 Accessed 6 Sep 2022.
- 525 13. Martínez JI, Montalbán EG, Bueno SJ, Martínez FM, Juliá AN et al. Monkeypox  
526 outbreak predominantly affecting men who have sex with men, Madrid, Spain, 26 April  
527 to 16 June 2022. *Eurosurveillance*. 2022; 27(27):2200471.
- 528 14. Selb R, Werber D, Falkenhorst G, Steffen G, Lachmann R et al. A shift from travel-  
529 associated cases to autochthonous transmission with Berlin as epicentre of the  
530 monkeypox outbreak in Germany, May to June 2022. *Eurosurveillance*. 2022;  
531 27(27):2200499.

- 532 15. WHO. Multi-country outbreak of monkeypox, External situation report #4 - 24 August  
533 2022. 4 edn. In: Emergency Situational Updates. World Health Organization. 2022.  
534 Accessed 29 Oct 2022.
- 535 16. Schmerling RH. What to Know About Monkeypox. In: Education. Harvard Medical  
536 School. 2022. <https://hms.harvard.edu/news/what-know-about-monkeypox>. Accessed 2  
537 Sep 2022.
- 538 17. Molteni M, Branswell H, Joseph A, Mast J. 10 key questions about monkeypox the world  
539 needs to answer. In: Health. STAT. 2022. [https://www.statnews.com/2022/08/30/10-key-](https://www.statnews.com/2022/08/30/10-key-questions-about-monkeypox-the-world-needs-to-answer/)  
540 [questions-about-monkeypox-the-world-needs-to-answer/](https://www.statnews.com/2022/08/30/10-key-questions-about-monkeypox-the-world-needs-to-answer/). Accessed 2 Sep 2022.
- 541 18. WHO. Vaccines and immunization for monkeypox: interim guidance, 24 August 2022.  
542 World Health Organization. 2022. [https://www.who.int/publications/i/item/WHO-MPX-](https://www.who.int/publications/i/item/WHO-MPX-Immunization-2022.2-eng)  
543 [Immunization-2022.2-eng](https://www.who.int/publications/i/item/WHO-MPX-Immunization-2022.2-eng). Accessed 29 Oct 2022.
- 544 19. Chowell G, Dahal S, Tariq A, Roosa K, Hyman JM et al. An ensemble n-sub-epidemic  
545 modeling framework for short-term forecasting epidemic trajectories: Application to the  
546 COVID-19 pandemic in the USA. PLOS Computational Biology. 2022;  
547 18(10):e1010602.
- 548 20. Chowell G, Tariq A, Hyman JM. A novel sub-epidemic modeling framework for short-  
549 term forecasting epidemic waves. BMC medicine. 2019; 17(1):1-18.
- 550 21. U.S. Monkeypox Case Trends Reported to CDC. Centers for Disease Control and  
551 Prevention. <https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html>.  
552 Accessed 19 Oct 2022.
- 553 22. Mathieu E, Peters F, Peters C. Monkeypox Data. <https://github.com/owid/monkeypox>.  
554 Accessed 21 Oct 2022.

- 555 23. Case Definitions for Use in the 2022 Monkeypox Response.  
556 <https://www.cdc.gov/poxvirus/monkeypox/clinicians/case-definition.html>. Accessed 29  
557 Oct 2022.
- 558 24. WHO. Multi-country monkeypox outbreak in non-endemic countries. In: Disease  
559 Outbreak News. World Health Organization. 2022.  
560 <https://www.who.int/emergencies/disease-outbreak-news/item/2022-DON385>. Accessed  
561 2 Sep 2022.
- 562 25. Chowell G, Hincapie-Palacio D, Ospina J, Pell B, Tariq A et al. Using phenomenological  
563 models to characterize transmissibility and forecast patterns and final burden of Zika  
564 epidemics. PLoS currents. 2016; 8.
- 565 26. Pell B, Kuang Y, Viboud C, Chowell G. Using phenomenological models for forecasting  
566 the 2015 Ebola challenge. Epidemics. 2018; 22:62-70.
- 567 27. Shanafelt DW, Jones G, Lima M, Perrings C, Chowell G. Forecasting the 2001 foot-and-  
568 mouth disease epidemic in the UK. EcoHealth. 2018; 15(2):338-347.
- 569 28. Banks HT, Hu S, Thompson WC. Modeling and inverse problems in the presence of  
570 uncertainty. CRC Press; 2014.
- 571 29. Roosa K, Luo R, Chowell G. Comparative assessment of parameter estimation methods  
572 in the presence of overdispersion: a simulation study. Math Biosci Eng. 2019; 16:4299-  
573 4313.
- 574 30. Hastie T, Tibshirani R, Friedman JH, Friedman JH. The elements of statistical learning:  
575 data mining, inference, and prediction, vol 2. Springer; 2009.
- 576 31. Hurvich CM, Tsai C-L. Regression and time series model selection in small samples.  
577 Biometrika. 1989; 76(2):297-307.

- 578 32. Sugiura N. Further analysts of the data by akaike's information criterion and the finite  
579 corrections: Further analysts of the data by akaike's. Communications in Statistics-theory  
580 and Methods. 1978; 7(1):13-26.
- 581 33. Burnham KP, Anderson DR. Model selection and multimodel inference: a practical  
582 information-theoretic approach. 2nd ed. New York, NY: Springer-Verlag 2002: p. 488.
- 583 34. Gneiting T, Raftery AE. Strictly proper scoring rules, prediction, and estimation. Journal  
584 of the American statistical Association. 2007; 102(477):359-378.
- 585 35. Kuhn M, Johnson K. Applied predictive modeling, vol 26. Springer; 2013.
- 586 36. Bracher J, Ray EL, Gneiting T, Reich NG. Evaluating epidemic forecasts in an interval  
587 format. PLoS computational biology. 2021; 17(2):e1008618.
- 588 37. Cramer EY, Ray EL, Lopez VK, Bracher J, Brennen A et al. Evaluation of individual and  
589 ensemble probabilistic forecasts of COVID-19 mortality in the United States.  
590 Proceedings of the National Academy of Sciences. 2022; 119(15):e2113561119.
- 591 38. Chowell G, Bleichrodt A, Dahal S. Monkeypox short term Forecasts, USA.  
592 <https://github.com/gchowell/monkeypox-usa/wiki>. Accessed 23 Oct 2022.
- 593 39. Chowell G, Bleichrodt A, Dahal S. Forecasts of national monkeypox incidence in the  
594 United States. <https://publichealth.gsu.edu/research/monkeypox-forecasting-center/>.  
595 Accessed 19 Oct 2022.
- 596 40. Delaney KP. Strategies adopted by gay, bisexual, and other men who have sex with men  
597 to prevent monkeypox virus transmission—United States, August 2022. MMWR  
598 Morbidity and mortality weekly report. 2022; 71.
- 599 41. Doucleff M, Huang P. Monkeypox cases in the U.S. are way down - can the virus be  
600 eliminated? In: Public Health. NPR. 2022. <https://www.npr.org/sections/health->

shots/2022/10/17/1129234501/monkeypox-cases-in-the-u-s-are-way-down-can-the-virus-be-eliminated. Accessed 28 Oct 2022.

42. Reardon S. What does the future look like for monkeypox? In: News Feature. nature. 2022. 250-252. <https://www.nature.com/articles/d41586-022-03204-7>. Accessed 28 Oct 2022.

43. Doherty IA, Padian NS, Marlow C, Aral SO. Determinants and consequences of sexual networks as they affect the spread of sexually transmitted infections. The Journal of infectious diseases. 2005; 191 Suppl 1:S42-S54.

44. Liljeros F, Edling CR, Amaral LAN. Sexual networks: implications for the transmission of sexually transmitted infections. Microbes and infection. 2003; 5(2):189-196.

45. Thomas JC, Tucker MJ. The development and use of the concept of a sexually transmitted disease core. Journal of Infectious Diseases. 1996; 174 Suppl 2:S134-S143.

46. Kupferschmidt K. Monkeypox cases are plummeting. Scientists are debating why. In: All News. Science. 2022. <https://www.science.org/content/article/monkeypox-cases-are-plummeting-scientists-are-debating-why>. Accessed 29 Oct 2022.

47. Soucheray S. Global monkeypox cases drop 22%. In: Featured News Topics. CIDRAP. 2022. <https://www.cidrap.umn.edu/news-perspective/2022/09/global-monkeypox-cases-drop-22>. Accessed 28 Oct 2022.

48. FACT SHEET: Biden-Harris Administration's Monkeypox Outbreak Response. In: Statements and Releases. The White House. 2022. <https://www.whitehouse.gov/briefing-room/statements-releases/2022/06/28/fact-sheet-biden-harris-administrations-monkeypox-outbreak-response/>. Accessed 28 Aug 2022.

49. Prevention. <https://www.cdc.gov/poxvirus/monkeypox/prevention/index.html>. Accessed 6 Sep 2022.
50. Huang P. Monkeypox cases are rising in the U.S. What's being done to stop the outbreak? Edited by Khalid A. In: Health. NPR. 2022. <https://www.npr.org/2022/07/29/1114417062/monkeypox-cases-are-rising-in-the-u-s-whats-being-done-to-stop-the-outbreak>. Accessed 29 Aug 2022.
51. Kates J, Artiga S, Dawson L. National Data Show Continuing Disparities in Monkeypox (MPX) Cases and Vaccinations Among Black and Hispanic People. In: Racial Equity and Health Policy. KFF. 2022. <https://www.kff.org/racial-equity-and-health-policy/issue-brief/national-data-show-continuing-disparities-in-mpx-monkeypox-cases-and-vaccinations-among-black-and-hispanic-people/#:~:text=MPX%20case%20rates%20among%20Black,and%208.3%20per%20100%2C000%2C%20respectively>. Accessed 29 Oct 2022.
52. Stobbe M, Johnson CK, Miller Z. US Data Reveals Racial Gaps in Monkeypox Vaccinations. In: Health News. U.S. News 2022. <https://www.usnews.com/news/health-news/articles/2022-08-26/monkeypox-vaccine-supply-now-sufficient-biden-officials-say>. Accessed 24 Oct 2022.
53. Wortman ZE, Kansagra SM, Tilson EC, Moore Z, Farrington DC et al. To Drive Equity In Monkeypox Response, States Should Learn From COVID-19. In: Health Affairs Forefront. HealthAffairs. 2022. <https://www.healthaffairs.org/content/forefront/drive-equity-monkeypox-response-states-should-draw-lessons-covid-19#:~:text=Health%20Affairs%20Forefront-,To%20Drive%20Equity%20In%20Monkeypox%20Response,Should%20Learn%20Fro>

m%20COVID%2D19&text=Since%20the%20US%20Department%20of,and%20who%20is%20getting%20vaccinated. Accessed 29 Oct 2022.

54. Kriss JL. Receipt of First and Second Doses of JYNNEOS Vaccine for Prevention of Monkeypox—United States, May 22–October 10, 2022. *MMWR Morbidity and Mortality Weekly Report*. 2022; 71.

55. Stone W, Huang P. The monkeypox outbreak may be slowing in the U.S., but health officials urge caution. In: *Public Health*. NPR. 2022. <https://www.npr.org/sections/health-shots/2022/08/26/1119659681/early-signs-suggest-monkeypox-may-be-slowing-in-the-u-s>. Accessed 6 Sep 2022.

56. Grover N. Monkeypox outbreak can be eliminated in Europe, WHO says. Edited by Birsal R, Baum B. In: *Europe*. Reuters. 2022. <https://www.reuters.com/world/europe/monkeypox-outbreak-can-be-eliminated-europe-who-officials-2022-08-30/>. Accessed 6 Sep 2022.

57. Miller MJ. Severe Monkeypox in Hospitalized Patients—United States, August 10–October 10, 2022. *MMWR Morbidity and Mortality Weekly Report*. 2022; 71.

58. 2022 Monkeypox Outbreak: Global Trends. [https://worldhealthorg.shinyapps.io/mpx\\_global/#section-fns3](https://worldhealthorg.shinyapps.io/mpx_global/#section-fns3). Accessed 29 Oct 2022.

59. Elsesser SA, Oldenburg CE, Biello KB, Mimiaga MJ, Safren SA et al. Seasons of risk: anticipated behavior on vacation and interest in episodic antiretroviral pre-exposure prophylaxis (PrEP) among a large national sample of US men who have sex with men (MSM). *AIDS and Behavior*. 2016; 20(7):1400-1407.

60. Mondal P, Shit L, Goswami S. Study of effectiveness of time series modeling (ARIMA) in forecasting stock prices. International Journal of Computer Science, Engineering and Applications. 2014; 4(2):13.
61. Tektaş M. Weather forecasting using ANFIS and ARIMA models. Environmental Research, Engineering and Management. 2010; 51(1):5-10.



**Figure 1.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for Brazil. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 2.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for Canada. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 3.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for England. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 4.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for France. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 5.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for Germany. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 6.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for Spain. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 7.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for the United States. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the CDC [21]. The black circles to the left of the vertical line represent the reported cases as of the Wednesday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date.

**Figure 8.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for the United States. The forecasts are derived from the weighted ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 9.** The overlayed forecasted and reported monkeypox cases for the weeks of 7/28/2022 through the week of 10/13/2022 for the World. The forecasts are derived from the weighted

ensemble sub-epidemic model using 10-week calibration data, and the reported cases are obtained from the OWID GitHub [22]. The black circles to the left of the vertical line represent the reported cases as of the Friday of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The black circles to the right of the vertical line represent the reported case counts (as of 10/21/2022) for the corresponding date. The vertical dashed black line indicates the start of the forecast period. For the week of 7/28/2022, data posted by the OWID team on 8/9/2022 was used to produce the forecast as it was the earliest version of data available.

**Figure 10.** The latest 4-week ahead forecasts of reported monkeypox cases for the week of 10/13/2022 derived from the top-ranked sub-epidemic model based on weekly cases using 10-week calibration data. The black circles to the left of the vertical line represent the reported cases as of the Wednesday (CDC forecast) or Friday (OWID forecast) of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The vertical dashed black line indicates the start of the forecast period.

**Figure 11.** The latest 4-week ahead forecasts of reported monkeypox cases for the week of 10/13/2022 derived from the second-ranked sub-epidemic model based on weekly cases using 10-week calibration data. The black circles to the left of the vertical line represent the reported cases as of the Wednesday (CDC forecast) or Friday (OWID forecast) of the forecast period; the solid red line corresponds to the best fit model; the dashed black lines correspond to the 95% prediction intervals. The vertical dashed black line indicates the start of the forecast period.

796

797 **Figure 12.** The latest 4-week ahead forecasts of reported monkeypox cases for the week of  
 798 10/13/2022 derived from the weighted ensemble sub-epidemic model based on weekly cases  
 799 using 10-week calibration data. The black circles to the left of the vertical line represent the  
 800 reported cases as of the Wednesday (CDC forecast) or Friday (OWID forecast) of the forecast  
 801 period; the solid red line corresponds to the best fit model; the dashed black lines correspond to  
 802 the 95% prediction intervals. The vertical dashed black line indicates the start of the forecast  
 803 period.

804

805

806

807

808

809

810

811

812

813

814

815

	Model	Brazil	Canada	England	France	Germany	Spain	US (OWID)	US (CDC)	World
Mean Absolute Error (MAE)	Top-ranked	<b>377.90</b>	<b>20.13</b>	<b>38.36</b>	119.13	<b>21.31</b>	<b>76.59</b>	1485.54	<b>1169.67</b>	1056.77
	2 <sup>nd</sup> ranked	749.38	25.41	46.50	<b>105.15</b>	42.28	154.15	<b>892.71</b>	2597.93	1403.50
	Ensemble (Weighted)	<b>377.90</b>	<b>20.13</b>	<b>38.36</b>	119.13	<b>21.31</b>	<b>76.59</b>	1485.54	<b>1169.67</b>	1056.77
	Ensemble (Unweighted)	408.27	22.04	39.80	107.87	23.22	108.64	1085.13	1325.64	<b>1015.21</b>
Mean Square Error (MSE)	Top-ranked	<b>383525.66</b>	1468.89	<b>3833.80</b>	45724.96	<b>806.13</b>	<b>12347.01</b>	6071637.86	<b>5346637.83</b>	2204026.11
	2 <sup>nd</sup> ranked	2413843.43	1420.74	4436.03	<b>37874.07</b>	3591.54	45935.30	<b>1366006.66</b>	57778292.62	3512916.37
	Ensemble (Weighted)	<b>383525.66</b>	1468.89	<b>3833.80</b>	45724.96	<b>806.13</b>	<b>12347.01</b>	6071637.86	<b>5346637.83</b>	2204026.11
	Ensemble (Unweighted)	485613.55	<b>1405.55</b>	3889.00	41981.04	869.00	29812.68	2087350.98	7742719.36	<b>1757084.06</b>
Percent coverage of the 95% prediction interval (PI)	Top-ranked	68.75	<b>87.50</b>	90.63	87.50	<b>100.00</b>	<b>100.00</b>	71.88	56.25	84.38
	2 <sup>nd</sup> ranked	68.75	81.25	<b>93.75</b>	<b>90.63</b>	93.75	93.75	87.50	<b>75.00</b>	90.63
	Ensemble (Weighted)	68.75	<b>87.50</b>	90.63	87.50	<b>100.00</b>	<b>100.00</b>	71.88	56.25	84.38
	Ensemble (Unweighted)	<b>75.00</b>	<b>87.50</b>	90.63	<b>90.63</b>	96.88	<b>100.00</b>	<b>93.75</b>	<b>75.00</b>	<b>93.75</b>
Weighted Interval Score (WIS)	Top-ranked	<b>276.22</b>	<b>16.42</b>	<b>26.48</b>	98.80	<b>13.74</b>	<b>55.81</b>	1021.17	<b>893.27</b>	677.85
	2 <sup>nd</sup> ranked	496.21	19.32	32.37	<b>91.24</b>	27.84	105.07	799.28	1568.86	834.45
	Ensemble (Weighted)	<b>276.22</b>	<b>16.42</b>	<b>26.48</b>	98.80	<b>13.74</b>	<b>55.81</b>	1021.17	<b>893.27</b>	677.85
	Ensemble (Unweighted)	337.07	17.28	28.36	92.81	17.40	68.06	<b>708.94</b>	1027.57	<b>669.14</b>

816

817 **Table 1. Mean performance metrics of the forecasts generated by the sub-epidemic models.**

818 The mean performance metrics of the forecasts generated by the sub-epidemic models`  
 819 performance across 8 sequential forecasting periods (Week of July 28<sup>th</sup> through the week of  
 820 September 15<sup>th</sup>, 2022) for each geographical area. Only weeks in which observed case data was  
 821 available are included. Values highlighted in bold correspond to best performing model for a  
 822 given geographical region and metric.

823

824

825

826

827

828

829

830

831

832

833

834



835

Week		Brazil	Canada	England	France	Germany	Spain	US (OWID)	U.S. (CDC)	World
07-28-2022	Median	8463.7	742.3	773.9	872.4	591.2	1391.2	4838.8	3972.2	20957.3
	LB	6067.5	622.3	322.9	245.6	234.1	0.0	2038.2	1482.7	14263.4
	UB	11783.6	887.6	1384.3	2322.0	972.4	5137.4	17645.5	14737.1	32121.5
08-04-2022	Median	1187.2	385.9	660.3	522.6	458.7	966.3	33042.3	31740.8	34936.8
	LB	651.6	215.0	224.7	62.0	167.6	0.0	21005.3	20265.5	24148.0
	UB	2841.9	621.8	1157.7	1316.6	767.2	3435.6	55553.7	52503.6	42706.4
08-11-2022	Median	2685.3	254.5	434.9	286.1	420.3	1237.7	6058.4	4301.5	22930.0
	LB	1477.3	143.3	79.0	0.0	162.3	0.0	2242.7	3118.5	15153.2
	UB	5348.1	385.7	848.3	924.7	696.3	3754.3	20689.6	5592.6	32717.9
08-18-2022	Median	1631.6	231.2	251.2	152.8	354.1	1158.6	6247.6	4539.4	18643.0
	LB	711.3	120.6	32.6	0.0	114.4	0.0	1816.2	3226.2	12818.4
	UB	3662.6	352.7	515.4	677.8	593.4	3503.7	15853.4	6067.3	25447.7
08-25-2022	Median	2312.1	185.7	147.6	609.1	277.7	806.8	3420.0	3756.9	15412.5
	LB	1288.4	97.3	11.7	0.0	57.8	0.0	610.6	2218.4	9456.3
	UB	3903.2	277.4	340.1	2517.0	506.4	2753.8	7594.1	5342.4	22458.5
09-01-2022	Median	1593.3	111.7	130.1	503.9	147.1	755.3	3824.4	3175.9	12899.5
	LB	768.7	8.0	9.9	0.0	0.0	0.0	571.0	1697.9	7794.2
	UB	2599.4	240.7	281.3	2252.0	410.0	2166.7	8101.4	4689.0	18540.1
09-08-2022	Median	1723.7	75.6	108.4	438.6	56.7	271.0	2978.7	2542.4	9097.0
	LB	866.6	1.9	0.0	0.0	0.0	0.0	223.6	959.6	5279.6
	UB	2648.9	180.9	267.2	1998.6	158.0	933.0	6706.9	4176.0	13323.9
09-15-2022	Median	2401.9	66.0	74.0	346.6	51.6	143.9	3826.9	2526.1	11764.0
	LB	844.3	0.0	0.0	0.0	0.0	0.0	690.5	999.5	5704.9
	UB	4116.9	415.6	733.7	1836.3	303.1	739.6	7379.2	4086.6	18545.3
09-22-2022	Median	2144.9	41.7	79.9	357.9	12.8	143.3	2958.6	2011.8	10205.4
	LB	875.0	0.0	0.0	0.0	0.0	0.0	265.3	768.4	4305.2
	UB	3452.4	354.2	734.6	1882.9	236.1	663.5	6078.7	3299.8	16332.0
09-29-2022	Median	1534.7	29.5	45.0	115.6	7.7	32.3	3365.1	1395.1	8853.4
	LB	320.1	0.0	0.0	0.0	0.0	0.0	326.2	377.7	3312.8
	UB	2898.0	223.8	701.1	1432.3	215.9	437.5	6758.5	2469.3	14514.1
10-06-2022	Median	1117.8	13.6	20.0	32.7	4.3	66.1	1017.4	931.4	5297.9
	LB	129.8	0.0	0.0	0.0	0.0	0.0	0.0	330.9	244.2
	UB	2240.8	129.0	574.3	1229.4	131.4	335.6	5154.0	1551.8	11508.3
10-13-2022	Median	878.9	14.2	2.7	10.3	1.5	43.0	1806.3	910.1	6231.5
	LB	25.0	0.0	0.0	0.0	0.0	0.0	0.0	245.3	487.8
	UB	1951.5	90.4	342.8	1088.0	125.7	315.6	5544.5	1603.5	12468.0


836 **Table 2. Predicted cumulative number of newly forecasted monkeypox cases and 95% PIs**  
 837 **for the top-ranked model.**

838 Predicted cumulative number of newly reported monkeypox cases and 95% PIs for each 4-week  
 839 ahead forecasts for the weeks of 7-28-2022 through 10-13-2022 based on a weekly cases using a  
 840 10-week calibration period for the top-ranked sub-epidemic model.


841

842


As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022



As of 10-6-2022




As of 10-13-2022







As of 8-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-8-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022



As of 10-6-2022




As of 10-13-2022







As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022




As of 10-6-2022




As of 10-13-2022




As of 7-28-2022




As of 8-4-2022




As of 8-11-2022




As of 8-18-2022




As of 8-25-2022




As of 9-1-2022




As of 9-8-2022




As of 9-15-2022




As of 9-22-2022




As of 9-29-2022



As of 10-6-2022




As of 10-13-2022




Monkeypox Cases


**World - OWID**




**United States - OWID**




**United States - CDC**




**Brazil - OWID**




**Spain - OWID**




**France - OWID**




**England - OWID**



**Germany - OWID**



**Canada - OWID**




Monkeypox Cases


Monkeypox Cases

Monkeypox Cases


World - OWID




United States - OWID




United States - CDC




Brazil - OWID




Spain - OWID




France - OWID




England - OWID



Germany - OWID




Canada - OWID






Monkeypox Cases


World - OWID



United States - OWID




United States - CDC




Monkeypox Cases


Brazil - OWID



Spain - OWID




France - OWID




Monkeypox Cases

England - OWID



Germany - OWID



Canada - OWID

